Monograph Details
|
|
Central Nervous System
> Psychosis
|
|
HALDOL DECANOATE INJ |
| Manufacturer |
|
Ortho-McNeil Neurologics, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Butyrophenone. |
| Generic Name |
|
Haloperidol (as decanoate) 50mg/mL, 100mg/mL; contains benzyl alcohol. |
| Also |
|
• HALDOL INJECTION
|
| Indications |
|
Treatment of schizophrenia when prolonged parenteral therapy required. |
| Children |
|
Not recommended. |
| Adults |
|
Individualize. Administer by deep IM every 4 weeks. Initially: 10–20 times previous daily dose of oral haloperidol. Stabilized on low daily oral dose, elderly, or debilitated: 10–15 times previous daily dose of oral haloperidol. Maintained on high dose antipsychotics, risk of relapse, or if tolerant: consider 20 times previous daily oral dose; then titrate downward subsequently. Max initial dose: 100mg; if conversion requires >100mg, then give balance in 3–7 days. Max: 450mg/month. |
| Contraindications |
|
Severe CNS depression. Coma. Parkinsonism. |
| Precautions |
|
Cardiovascular disease. QT-prolonging conditions. Electrolyte disturbances (eg, hypokalemia, hypomagnesemia). Hypothyroidism. Seizures. Thyrotoxicosis. Avoid abrupt cessation. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
CNS depression potentiated with alcohol, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval. Monitor anticoagulants, rifampin. |
| Adverse Reactions |
|
Tardive dyskinesia, neuroleptic malignant syndrome, extrapyramidal symptoms, hyperpyrexia, heat stroke, bronchopneumonia, cardiovascular effects, GI upset, anticholinergic effects; QT prolongation, Torsades de Pointes. |
| How Supplied |
Inj (1mL amps)—10
Decanoate 50 (1mL amps)—3, 10
Decanoate 100 (1mL amps)—5 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
